Table 1. Characteristics of studies on mTOR expression.
| First authe | Country | year | No. of patients (mTOR high/low) | Age (y) | Histological type(SCC/ADC/Other) | Stage (I/II/III/IV) | Univariate HR estimated | Univariate HR(95%CI) | Multivariate HR estimated | Multivariate HR(95%CI) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tony D.[21] | Italy | 2010 | 134(73/61) | > = 65y, 57 <65y, 77 | 56/41/37 | 91/43/0/0 | HR 95%CI | 1.77(1.17–2.73) | HR 95%CI | 1.66(1.01–2.74) | ||
| Gately K.[22] | UK | 2012 | 141(101/40) | > = 65y, 67 <65y, 74 | 67/60/14 | 97/44/0/0 | HR 95%CI | 1.85(0.98–3.49) | HR 95%CI | 2.18(1.12–4.23) | ||
| Liu D.[23] | China | 2011 | 172(106/28) | > = 60y, 91 <60y, 81 | 75/77/20 | I-II,85 III-IV, 87 | HR 95%CI | 0.645(0.377–1.103) | NA | NA | ||
| Valsamo K.[24] | USA | 2009 | 167(94/73) | 64 | NA | NA | HR 95%CI | 0.44(0.22–0.88) | HR 95%CI | 0.48(0.24–0.98) |
Abbreviation: SCC, squamous cell carcinoma; ADC, adenocarcinoma; HR hazard ratio; NA, no available